Anacetrapib, an experimental drug to prevent heart attacks and strokes, is potentially one of the biggest medicines in development at Merck. But Wall Street analysts are skeptical it will ever reach the market thanks to the failures of similar pills from Pfizer and Roche. And now new data give investors yet another reason to doubt the medication.
Help employers find you! Check out all the jobs and post your resume.
